Recruitment
Clinical Trial Center of Fuda Cancer Hospital affiliated to Jinan University
Phase IV clinical study of rmhTNF-NC (TianEnFu) for treating malignant tumors
A multi-center study on the safety and efficacy of rmhTNF-NC (TianEnFu) for treating malignant tumors applied by Shanghai Weike Bio-Pharmaceutical Co., Ltd. is conducted in 80-100 hospitals in Nanjing, Beijing, Shanghai, Hangzhou, Guangzhou and Fujian, etc. so 2,000 patients with malignant tumors can benefit from this study.
Tumor necrosis factor α (TNF-α) is the most potent anti-tumor cytokine to date, and is the only factor among all cytokines that directly kills tumor cells. Marketed in 2004, rmhTNF-NC is an upgraded product after structural modification of TNF-α with a positive effect on non-small cell lung cancer and non-Hodgkin's lymphoma with combination of chemotherapy.
If you are or your friend is: aged 18-75, non-small cell lung cancer patient, and willing to receive appropriate treatment, please join phase IV clinical study of rmhTNF-NC (TianEnFu) conducted by Shanghai Weike Bio-Pharmaceutical Co., Ltd. in Fuda Cancer Hospital affiliated to Jinan University.
If you want more details, please feel free to contact us in 0086-20-38993956.
We sincerely wish you get well soon!